ATE519782T1 - Peptide und ihre verwendung zur behandlung von hiv infektionen - Google Patents
Peptide und ihre verwendung zur behandlung von hiv infektionenInfo
- Publication number
- ATE519782T1 ATE519782T1 AT03813584T AT03813584T ATE519782T1 AT E519782 T1 ATE519782 T1 AT E519782T1 AT 03813584 T AT03813584 T AT 03813584T AT 03813584 T AT03813584 T AT 03813584T AT E519782 T1 ATE519782 T1 AT E519782T1
- Authority
- AT
- Austria
- Prior art keywords
- amino acid
- phenylalanine
- cysteine
- acid
- alanine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 208000031886 HIV Infections Diseases 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 7
- 235000008729 phenylalanine Nutrition 0.000 abstract 7
- 150000001413 amino acids Chemical group 0.000 abstract 6
- 235000018417 cysteine Nutrition 0.000 abstract 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 5
- 235000004279 alanine Nutrition 0.000 abstract 5
- 235000001014 amino acid Nutrition 0.000 abstract 5
- 229940024606 amino acid Drugs 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 230000002209 hydrophobic effect Effects 0.000 abstract 4
- BWKMGYQJPOAASG-SECBINFHSA-N D-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN[C@@H](C(=O)O)CC2=C1 BWKMGYQJPOAASG-SECBINFHSA-N 0.000 abstract 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
- 239000004471 Glycine Substances 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 3
- 235000013922 glutamic acid Nutrition 0.000 abstract 3
- 239000004220 glutamic acid Chemical group 0.000 abstract 3
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical group OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 2
- 229930182820 D-proline Chemical group 0.000 abstract 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 235000003704 aspartic acid Nutrition 0.000 abstract 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 2
- 238000012217 deletion Methods 0.000 abstract 2
- 229960000310 isoleucine Drugs 0.000 abstract 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 2
- 235000014705 isoleucine Nutrition 0.000 abstract 2
- 235000018977 lysine Nutrition 0.000 abstract 2
- 239000004474 valine Substances 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 229930182817 methionine Chemical group 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02028465 | 2002-12-19 | ||
| PCT/EP2003/014654 WO2004056871A2 (en) | 2002-12-19 | 2003-12-19 | Peptides and their use for the treatment of hiv infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE519782T1 true ATE519782T1 (de) | 2011-08-15 |
Family
ID=32668727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03813584T ATE519782T1 (de) | 2002-12-19 | 2003-12-19 | Peptide und ihre verwendung zur behandlung von hiv infektionen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7655629B2 (de) |
| EP (1) | EP1572743B1 (de) |
| JP (1) | JP4505336B2 (de) |
| AT (1) | ATE519782T1 (de) |
| AU (1) | AU2003303218A1 (de) |
| CA (1) | CA2509423A1 (de) |
| ES (1) | ES2369771T3 (de) |
| WO (1) | WO2004056871A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210528A1 (en) * | 1999-03-05 | 2010-08-19 | Leland Shapiro | Compositions, methods and uses for inhibition and/or treatment of influenza infection |
| US20100144630A1 (en) * | 1999-03-05 | 2010-06-10 | Leland Shapiro | Compositions, methods and uses for inhibition and/or treatment of influenza infection |
| JP4782782B2 (ja) * | 2004-06-18 | 2011-09-28 | イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング | オリゴマーペプチドおよびｈｉｖ感染症の治療のためのその使用 |
| KR20080074924A (ko) * | 2005-11-02 | 2008-08-13 | 암브룩스, 인코포레이티드 | 생합성 폴리펩티드 융합 저해제 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0616614A1 (de) * | 1991-04-18 | 1994-09-28 | The Uab Research Foundation | Zusammensetzungen und methoden zur inhibition von elastase |
| US5972901A (en) * | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
| WO2001008708A2 (en) * | 1999-07-29 | 2001-02-08 | Case Western Reserve University | Enhanced delivery via serpin enzyme complex receptor ligands |
| US6296164B1 (en) | 1999-07-13 | 2001-10-02 | Dale Medical Products, Inc. | Medical device holder |
| JP4813720B2 (ja) * | 1999-11-08 | 2011-11-09 | イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヒト循環ウイルス阻害ペプチド（ｖｉｒｉｐ）及びその使用 |
-
2003
- 2003-12-19 AT AT03813584T patent/ATE519782T1/de active
- 2003-12-19 ES ES03813584T patent/ES2369771T3/es not_active Expired - Lifetime
- 2003-12-19 EP EP03813584A patent/EP1572743B1/de not_active Expired - Lifetime
- 2003-12-19 CA CA002509423A patent/CA2509423A1/en not_active Abandoned
- 2003-12-19 US US10/539,627 patent/US7655629B2/en not_active Expired - Fee Related
- 2003-12-19 AU AU2003303218A patent/AU2003303218A1/en not_active Abandoned
- 2003-12-19 WO PCT/EP2003/014654 patent/WO2004056871A2/en not_active Ceased
- 2003-12-19 JP JP2004561391A patent/JP4505336B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003303218A8 (en) | 2004-07-14 |
| EP1572743A2 (de) | 2005-09-14 |
| JP4505336B2 (ja) | 2010-07-21 |
| EP1572743B1 (de) | 2011-08-10 |
| US20070072805A1 (en) | 2007-03-29 |
| WO2004056871A3 (en) | 2004-10-21 |
| ES2369771T3 (es) | 2011-12-05 |
| CA2509423A1 (en) | 2004-07-08 |
| WO2004056871A2 (en) | 2004-07-08 |
| AU2003303218A1 (en) | 2004-07-14 |
| US7655629B2 (en) | 2010-02-02 |
| JP2006522584A (ja) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20070296L (no) | Oligomere peptider og deres anvendelse for behandling av HIV infeksjoner | |
| DK0512042T3 (da) | GLP-1-analoger anvendelige ved diabetesbehandling | |
| ATE368053T1 (de) | Antimikrobielle peptide | |
| DE60333758D1 (de) | Prevention und Verringerung von Ischemia | |
| FR2766191B1 (fr) | Peptides anti-microbiens de crustaces | |
| ATE482272T1 (de) | Zytokinproteinfamilie | |
| WO2005123771B1 (en) | Oligomeric peptides and their use for the treatment of hiv infections | |
| DE69840024D1 (de) | Antimikrobielle Peptide, abstammend von Ubiquicidin | |
| DE602004028266D1 (de) | Angiogene peptide und ihre verwendungen | |
| ATE519782T1 (de) | Peptide und ihre verwendung zur behandlung von hiv infektionen | |
| CY1109946T1 (el) | Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων | |
| DE69935414D1 (en) | Humanes btrcp protein | |
| ATE245168T1 (de) | Peptide, die anti-zellanhaftungsaktivität aufweisen | |
| DK1504036T3 (da) | Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet | |
| DE60313970D1 (de) | Lineare kationische peptide mit fungizider wirksamkeit | |
| DE69117965D1 (de) | Peptide, welche hiv-retroviren-hemmende antikörper induzieren, sowie gegen diese peptide gerichtete antikörper | |
| SE9700301D0 (sv) | New compound | |
| ATE411812T1 (de) | Peptide zur behandlung von infektionen mit dem herpes-virus | |
| EP0361956A3 (de) | Expression von rekombinanten Proteinen mit niedrigem Molekulargewicht | |
| EA200401611A1 (ru) | Пептиды gp41 и способы ингибирования слияния вич с клетками-мишенями на их основе | |
| WO2005094870A3 (en) | Use of osteopontin fragment svvglr-derived peptides for the treatment of ischemic diseases | |
| CY1115911T1 (el) | Τροποποιημενα πολυπεπτιδια περιοχης kunitz και η χρηση τους στην μειωση της ισχαιμιας ή της εκκινησης μιας συστημικης φλεγμονωδους ανταποκρισης που σχετιζεται με μια χειρουργικη επεμβαση | |
| ATE207496T1 (de) | Neue peptide und nootroper wirkstoff | |
| TH36116A (th) | แอนตีบอดีแบบใหม่ สารออกฤทธิ์-เรนิน ที่ประกอบด้วยแอนติบอดีชนิดเดียวกันนี้ และรีเอเจนท์สำหรับตรวจวิเคราะห์โพรเรนินโดยใช้แอนติบอดีดังกล่าว | |
| TH9693B (th) | แอนตีบอดีแบบใหม่ สารออกฤทธิ์-เรนิน ที่ประกอบด้วยแอนติบอดีชนิดเดียวกันนี้ และรีเอเจนท์สำหรับตรวจวิเคราะห์โพรเรนินโดยใช้แอนติบอดีดังกล่าว |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1572743 Country of ref document: EP |